Toluene

Toluene

SCHEMBL1201404

CC(=O)O.CCCCCC.Cc1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Toluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.50
CES1 P23141 4/20 0.50
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
ACHE P22303 1/20 0.50
NAAA Q02083 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPK1 P28482 1/20 0.46
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
PCSK9 Q8NBP7 1/20 0.45
EPHX1 P07099 3/20 0.44
EPHX2 P34913 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL2357321 0.95 CES2 (0.50) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL8853666 0.93 CES2 (0.48) CES2CES1TSHRLMNAALOX12
Heptane SCHEMBL2077664 0.93 CES2 (0.52) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL1487693 0.91 CES2 (0.47) CES2CES1TSHRLMNAALOX12
Heptane SCHEMBL9819586 0.90 CES2 (0.49) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL8635446 0.88 LMNA (0.58) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL10941851 0.88 TSHR (0.65) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL18640410 0.88 TSHR (0.65) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL2990240 0.88 TSHR (0.65) CES2CES1TSHRLMNAALOX12
Toluene SCHEMBL6257976 0.88 TSHR (0.65) CES2CES1TSHRLMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2702150-B1 LIPASE VARIANTS HAVING INCREASED ENZYME SPECIFICITY OR ENHANCED TRANS-SELECTIVITY, AND METHODS OF USE FRITO LAY TRADING CO GMBH (CH) 2016-02-10 EP disclosed
US-9096525-B2 Iminipyridine derivatives and their uses as microbiocides SYNGENTA CROP PROTECTION, LLC (US) 2015-08-04 US disclosed
EP-2702150-A1 LIPASE VARIANTS HAVING INCREASED ENZYME SPECIFICITY OR ENHANCED TRANS-SELECTIVITY, AND METHODS OF USE Frito-Lay Trading Company GmbH (CH) 2014-03-05 EP disclosed
US-20130338105-A1 IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES SYNGENTA CROP PROTECTION LLC (US) 2013-12-19 US disclosed
US-8513286-B2 Iminipyridine derivatives and their uses as microbiocides SYNGENTA CROP PROTECTION LLC (US) 2013-08-20 US disclosed
WO-2012146935-A1 LIPASE VARIANTS HAVING INCREASED ENZYME SPECIFICITY OR ENHANCED TRANS-SELECTIVITY, AND METHODS OF USE FRITO-LAY TRADING COMPANY, GMBH (CH) 2012-11-01 WO disclosed
US-20110046088-A1 IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES SYNGENTA CROP PROTECTION, INC. (US) 2011-02-24 US disclosed
EP-2125734-A2 NOVEL MICROBIOCIDES Syngeta Participations AG (CH) 2009-12-02 EP disclosed
WO-2008101682-A2 IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046088-A1 IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES CD14, MYADM, MPO CES2 970/4885CES1 1563/4885TSHR 4222/4885
US-20130338105-A1 IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES CD14, MYADM, MPO CES2 797/4885CES1 1528/4885TSHR 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.